| IELSG45 | Randomized phase II trial on fitness- and comorbidity- tailored treatment in elderly patients with newly diagnosed primary CNS lymphoma (FIORELLA Trial) |
| Participants required: | 208 |
| Investigator responsible(s): | A. Ferreri |
| Objective(s): | Aim of the study is to assess the safety and efficacy of the combination of rituximab and ibrutinib in EMZL patients and to explore its activity in SMZL and NMZL as exploratory subset.The primary objective of this randomized phase II trial is to compare the efficacy of a new maintenance treatment consisting of oral lenalidomide with the oral procarbazine maintenance currently in use, in elderly (≥70 years) patients with newly diagnosed PCNSL eligible to receive HD-MTX-based induction chemo-immunotherapy. Aim of the study is to assess the safety and efficacy of the combination of rituximab and ibrutinib in EMZL patients and to explore its activity in SMZL and NMZL as exploratory subset. |
